News
Lawmakers pass regenerative medicine act
Lawmakers have passed the Regenerative Medicine Act. The act provides a legal basis for conducting research and development on regenerative medicine, technology control and cell sources for patients in emergency needs.
It stipulates that regenerative medicine must undergo human trials before execution and that non-medical facilities will no longer be allowed to offer regenerative medicine treatments.
Entities or individuals found to be in violation of that stipulation face a maximum fine of NT$20 million. However, two types of conditions are excluded from the restrictions on human trials. They are treatments for compassionate use and cases previously approved by central government authorities before the Act's passage.
Compassionate use refers to treatment options that allow the use of unauthorized medicines or products in development when no adequate medicine or equipment is accessible for the emergency needs of patients with a life-threatening disease or severe disability.
